

The original disclosure in Japanese was released on Nov. 9, 2023 at 15:30 (GMT+9)

Consolidated Financial Statements for the Second Quarter Ended September 30, 2023 FY2024 (April 1, 2023 - March 31, 2024) [UNAUDITED]

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (PRIME section)
 Code number: 2531
 URL: <https://www.takara.co.jp/>
 Company representative: Mutsumi Kimura, President
 Contact: Masakazu Usami, General Manager of Public Relations& Investor Relations Dept.
 TEL: (075)241-5124

Quarterly statement filing date(as planned): November 13, 2023

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the six months ended September 30, 2023 (April 1, 2023 – September 30, 2023)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ended September 30, 2023		Six months ended September 30, 2022	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	163,172	(0.7)	164,279	16.3
Operating income (loss)	12,464	(36.5)	19,614	(9.3)
Ordinary income (loss)	13,032	(34.7)	19,972	(8.7)
Net income (loss) attributable to owners of the parent	8,043	(26.0)	10,873	8.2
Net income (loss) per share (Yen)	40.69		55.00	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	26,272	(13.0)	30,213	43.5

(2) Consolidated financial position

	As of September 30, 2023	As of March 31, 2023
	(Millions of yen)	(Millions of yen)
Total assets	420,865	399,174
Net assets	272,071	255,318
Equity ratio (%)	52.2	51.1
(Reference) Equity	219,688	203,951

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2023	Year ending March 31, 2024	Year ending March 31, 2024 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	38.00	-	27.00
Annual	38.00	-	27.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

3. Forecast for the year ending March 31, 2024 (April 1, 2023 - March 31, 2024)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2024	
	(Millions of yen)	(%)
Net sales	341,000	(2.8)
Operating income (loss)	21,700	(42.8)
Ordinary income (loss)	22,500	(41.9)
Net income (loss) attributable to owners of the parent	15,000	(29.3)
Net income per share (Yen)	75.87	

Note: Correction of financial forecast from the most recent financial forecast: Yes

4. Others

- (1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No
- (2) Accounting procedures specific to quarterly consolidated financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - 1) Changes based on revisions of accounting standard: No
 - 2) Changes other than ones based on revisions of accounting standard: No
 - 3) Changes in accounting estimates: No
 - 4) Restatement: No
- (4) Number of outstanding shares (common stock)
 - 1) Number of outstanding shares at the end of each period (Treasury stocks are included):
 - As of September 30, 2023 : 199,699,743 shares
 - As of March 31, 2023 : 199,699,743 shares
 - 2) Number of treasury stocks at the end of each period:
 - As of September 30, 2023 : 1,995,673 shares
 - As of March 31, 2023 : 1,995,612 shares
 - 3) Average number of outstanding shares in each period
 - Six months ended September 30, 2023 : 197,704,122 shares
 - Six months ended September 30, 2022 : 197,704,145 shares

Contents of the attached document

1. Qualitative Information for the Six Months Ended September 30, 2023	2
(1) Consolidated Financial Results	2
(2) Consolidated Financial Position	3
(3) Qualitative Information Regarding Consolidated Forecasts	4
2. Consolidated Quarterly Financial Statements and Primary Notes	6
(1) Consolidated Balance Sheets	6
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	8
(Consolidated Statements of Income)	8
(For the Six Months Ended September 30, 2023 and 2022)	
(Consolidated Statements of Comprehensive Income)	9
(For the Six Months Ended September 30, 2023 and 2022)	
(3) Consolidated Statements of Cash Flows.....	10
(4) Notes to Consolidated Financial Statements	11
(Notes on Premise of Going Concern)	11
(Notes on Material Changes in Shareholders' Equity)	11
(Segment Information)	11
(Significant Subsequent Events)	12
○ Supplement for the Consolidated Quarterly Financial Statements	

1. Qualitative Information for the Six Months Ended September 30, 2023

(1) Consolidated Financial Results

In the six months ended September 30, 2023, net sales decreased 0.7% year on year to ¥163,172 million, gross profit decreased 4.2% year on year to ¥55,459 million, and SG&A expenses increased 12.4% year on year to ¥42,995 million. Operating income decreased 36.5% year on year to ¥12,464 million, ordinary income decreased 34.7% year on year to ¥13,032 million, and net income attributable to owners of the parent decreased 26.0% year on year to ¥8,043 million.

Results by business segment were as follows.

[Takara Shuzo]

In the six months ended September 30, 2023, although sales of light-alcohol refreshers and raw alcohol increased year on year, shochu, sake, and *Hon Mirin* decreased.

As a result, net sales for Takara Shuzo decreased 1.0% year on year to ¥61,190 million. Cost of sales decreased 5.3% year on year to ¥45,216 million, mainly due to a change in the sales mix, despite the continued impact of rising raw material prices. Gross profit increased 13.6% year on year to ¥15,974 million. SG&A expenses were in line with the equivalent period of the previous fiscal year, increasing 0.2% year on year to ¥12,021 million. Operating income was up 91.9% year on year to ¥3,952 million.

[Takara Shuzo International Group]

In the six months ended September 30, 2023, net sales of the Overseas Alcoholic Beverages Business increased year on year mainly due to continued growth in sales of whiskey in the U.S. and U.K. as well as an increase in sales of sake. Net sales of the Japanese Food Wholesale Business in overseas markets also increased as the eating and drinking establishment market continued to perform well, with the development of new business bases also contributing positively.

As a result, net sales for the Takara Shuzo International Group increased 21.1% year on year to ¥77,164 million. Cost of sales increased 20.7% year on year to ¥52,786 million in line with the increase in net sales. Consequently, gross profit increased 22.0% year on year to ¥24,377 million. SG&A expenses were up 26.5% year on year to ¥18,120 million, primarily due to an increase in personnel expenses and transportation costs, and operating income was up 10.6% year on year to ¥6,256 million.

[Takara Bio Group]

In the six months ended September 30, 2023, sales of testing-related reagents decreased due to changes in the legal categorization of COVID-19. As a result, net sales for the Takara Bio Group decreased 41.3% year on year to ¥19,116 million. Cost of sales decreased 45.3% year on year to ¥5,772 million, mainly due to a decrease in net sales. Consequently, gross profit decreased 39.4% year on year to ¥13,343 million. SG&A expenses were up 7.0% year on year to ¥11,933 million, primarily due to increases in personnel expenses and R&D expenses. Operating income decreased 87.0% year on year to ¥1,410 million.

[Other]

In the six months ended September 30, 2023, net sales of the Other segment decreased 4.6% year on year to ¥14,866 million due to decreased sales in the transportation business and the printing business. Cost of sales decreased 5.0% year on year to ¥12,729 million. Consequently, gross profit decreased 2.2% year on year to ¥2,136 million. SG&A expenses increased 0.2% year on year to ¥943 million, and operating income was down 4.0% year on year to ¥1,193 million.

Breakdown of sales results by product category

Segment		Equivalent Period of Previous Fiscal Year (From April 1, 2022, to September 30, 2022)	Period under Review (From April 1, 2023, to September 30, 2023)	YoY Comparison
	Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo	Shochu	19,998	17,469	(12.6)
	Sake	4,697	4,252	(9.5)
	Light-alcohol refreshers	20,525	21,782	6.1
	Other alcoholic beverages	2,823	2,750	(2.6)
	<i>Hon Mirin</i>	4,710	4,546	(3.5)
	Other seasonings	4,321	4,447	2.9
	Raw alcohol, etc.	4,743	5,941	25.2
	Total	61,820	61,190	(1.0)
Takara Shuzo International Group	Overseas Alcoholic Beverages Business	8,287	10,262	23.8
	Japanese Food Wholesales Business in overseas markets	56,421	68,084	20.7
	Other	2,812	215	(92.4)
	Elimination of intra-Group transaction on consolidation	(3,791)	(1,397)	—
	Total	63,730	77,164	21.1
Takara Bio Group				
	Reagents	27,565	14,949	(45.8)
	Instruments	694	411	(40.7)
	CDMO	3,183	2,702	(15.1)
	Gene therapy	1,144	1,052	(8.0)
Total		32,587	19,116	(41.3)
Reported segment total		158,138	157,471	(0.4)
Other		15,577	14,866	(4.6)
Segment total		173,715	172,338	(0.8)
Sales not allocated to business segments and intersegment transactions		(9,435)	(9,165)	—
Total		164,279	163,172	(0.7)

Note: 1. Amounts include alcohol tax.

(2) Consolidated Financial Position

As of September 30, 2023, current assets were ¥240,349 million, a decrease of ¥1,164 million compared with that at the end of the previous fiscal year. This was primarily due to a decrease in cash and deposits of ¥7,453 million, despite increases in notes and accounts receivable-trade and merchandise and finished goods of ¥1,646 million and ¥3,189 million, respectively.

Noncurrent assets were ¥180,516 million, an increase of ¥22,855 million compared with that at the end of the previous fiscal year. This was primarily due to increases in property, plant and equipment of ¥11,856 million, mainly due to increases in buildings and structures and construction in progress, intangible assets of ¥1,048 million, and investments and other assets of ¥9,950 million due to an increase in the market valuation of investment securities.

As a result, total assets were ¥420,865 million, an increase of ¥21,691 million compared with that at the end of the previous fiscal year.

As of September 30, 2023, current liabilities were ¥76,847 million, an increase of ¥9,392 million compared with that at the end of the previous fiscal year. This was primarily due to increases in short-term loans payable of ¥5,160 million, current portion of bonds of ¥5,000 million, and accrued alcohol tax of ¥3,458, despite a decrease in other under current liabilities of

¥4,698 million due to decreases in accrued payments. Noncurrent liabilities were ¥71,946 million, a decrease of ¥4,454 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in bonds payable of ¥5,000 million and long-term loans payable of ¥4,703 million, despite an increase in other under noncurrent liabilities of ¥5,303 million.

As a result, total liabilities were ¥148,794 million, an increase of ¥4,938 million compared with that at the end of the previous fiscal year.

As of September 30, 2023, total net assets were ¥272,071 million, an increase of ¥16,753 million compared with that at the end of the previous fiscal year. This was primarily due to increases in valuation difference on available-for-sale securities of ¥4,688 million and foreign currency translation adjustment of ¥10,416 million due to the ongoing weakening of the yen.

As a result, the equity ratio totaled 52.2%, compared with 51.1% at the end of the previous fiscal year.

In the six months ended September 30, 2023, net cash provided by operating activities increased ¥7,691 million year on year to ¥14,922 million primarily due to income before income taxes of ¥12,984 million, depreciation and amortization of ¥4,796 million, an increase in accrued alcohol tax of ¥3,458 million, a decrease in other current liabilities of ¥2,453 million, and ¥3,319 million in income taxes paid.

Net cash used in investing activities resulted in expenditure of ¥15,796 million, an increase in expenditure of ¥6,243 million compared to the same period of the previous fiscal year primarily due to purchase of property, plant and equipment and intangible assets of ¥14,540 million.

Net cash used in financing activities resulted in expenditure of ¥9,711 million, a decrease in expenditure of ¥11,913 million compared to the same period of the previous fiscal year primarily due to cash dividends paid of ¥7,497 million.

As a result, cash and cash equivalents as of September 30, 2023, including effect of exchange rate change on cash and cash equivalents, stood at ¥84,446 million, down ¥7,339 million from the previous fiscal year-end.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the full-year consolidated results forecasts published on May 11, 2023 in consideration of recent performance trends.

With regard to the outlook for each segment for the full year ending March 31, 2024, we expect to fall short of our previous forecast owing to lower than expected sales volumes of *Hon Mirin*, raw alcohol, etc., for Takara Shuzo. With regard to operating income, although net sales will not meet our targets, we expect to exceed our previous forecast owing to efforts to decrease our SG&A expenses in spite of improvements we have made in terms of advertising expenses which we have achieved through efforts to keep a lid on rising costs and through efficient use of sales promotion expenses.

With regard to the Takara Shuzo International Group, we expect that net sales will fall short of our previous forecast owing to an ongoing slowdown of consumer spending in response to inflation. We also expect operating income to fall short of our previous forecasts owing to a predicted failure to meet our targets for gross profit as a result of a drop in net sales.

With regard to net sales of the Takara Bio Group, we expect that sales from the business for reagents and instruments and the CDMO business (genetic analysis) will fall short of our previous forecast owing to a slump in the global life sciences R&D market in response to prolonged inflation and an economic downturn and because of increased price competition for products and services. We also expect operating income to fall short of our previous forecasts owing to a predicted failure to meet our targets for gross profit as a result of a drop in net sales.

As a result of the above, net sales, operating income, and ordinary income are all expected to fall short of our previous forecasts. We have not made any changes to our previous forecast for net income attributable to owners of the parent as extraordinary income will be recorded due to sales of cross-shareholdings. The details of the consolidated results forecasts and the results forecasts for each segment are described on pages 10/15-13/15 in “Supplement for the Consolidated Financial Statements.”

Note: Today (November 9, 2023), the Company subsidiary Takara Bio Inc. (listed on the Prime Market of the Tokyo Stock Exchange with securities code number 4974) also revised its consolidated results forecasts for the full-year consolidated results forecast ending March 31, 2024, published in the financial statements on May 11, 2023.

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2024)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published May 11, 2023)	(Millions of yen) 355,000	(Millions of yen) 26,300	(Millions of yen) 26,800	(Millions of yen) 15,000	(Yen) 75.87
Revised forecast (B)	341,000	21,700	22,500	15,000	75.87
Difference (B – A)	(14,000)	(4,600)	(4,300)	—	—
Difference (%)	(3.9)	(17.5)	(16.0)	—	—
Reference : Business results for previous fiscal year (Ended March 31, 2023)	350,665	37,945	38,706	21,206	107.26

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2023	As of Sept. 30, 2023
Assets		
Current assets		
Cash and deposits	96,820	89,367
Notes and accounts receivable-trade	69,717	71,363
Merchandise and finished goods	57,812	61,002
Work in process	1,718	2,132
Raw materials and supplies	7,372	7,577
Other	8,765	9,589
Allowance for doubtful accounts	(694)	(684)
Total current assets	241,513	240,349
Noncurrent assets		
Property, plant and equipment	88,890	100,747
Intangible assets		
Goodwill	10,668	11,505
Other	5,262	5,474
Total intangible assets	15,931	16,980
Investments and other assets		
Investment securities	30,573	37,373
Other	22,328	25,478
Allowance for doubtful accounts	(64)	(63)
Total investments and other assets	52,838	62,789
Total noncurrent assets	157,661	180,516
Total assets	399,174	420,865

	As of Mar. 31, 2023	As of Sept. 30, 2023
Liabilities		
Current liabilities		
Notes and accounts payable-trade	21,775	22,126
Short-term loans payable	4,919	10,079
Current portion of bonds	—	5,000
Accrued alcohol tax	5,815	9,274
Accrued expenses	6,368	6,019
Income taxes payable	2,220	2,824
Provision	3,622	3,488
Other	22,733	18,035
Total current liabilities	67,454	76,847
Noncurrent liabilities		
Bonds payable	20,000	15,000
Long-term loans payable	15,186	10,482
Net defined benefit liability	8,925	8,872
Other	32,288	37,591
Total noncurrent liabilities	76,401	71,946
Total liabilities	143,856	148,794
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	1,994	1,994
Retained earnings	163,825	164,356
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	177,363	177,893
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	12,974	17,663
Deferred gains or losses on hedges	286	290
Foreign currency translation adjustment	13,686	24,103
Remeasurements of defined benefit plans	(359)	(261)
Total accumulated other comprehensive income	26,588	41,795
Noncontrolling interests	51,366	52,382
Total net assets	255,318	272,071
Total liabilities and net assets	399,174	420,865

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(For the Six Months Ended September 30, 2023 and 2022)

(Millions of Yen)

	FY2022 (Apr. 1, 2022 – Sept. 30, 2022)	FY2023 (Apr. 1, 2023 – Sept. 30, 2023)
Net sales	164,279	163,172
Cost of sales	106,400	107,713
Gross profit	57,879	55,459
Selling, general and administrative expenses	38,264	42,995
Operating income	19,614	12,464
Nonoperating income		
Dividends income	445	496
Other	452	551
Total nonoperating income	898	1,048
Nonoperating expenses		
Interest expenses	149	184
Share of loss of entities accounted for using equity method	113	—
Foreign exchange losses	113	—
Provision for loss on litigation	—	109
Other	163	185
Total nonoperating expenses	539	480
Ordinary income	19,972	13,032
Extraordinary income		
Gain on sale of noncurrent assets	252	28
Gain on sale of investment securities	—	8
Insurance claim income	652	—
National subsidies	63	—
Total extraordinary income	967	36
Extraordinary loss		
Loss on sale and retirement of noncurrent assets	45	84
Loss on tax purpose reduction entry of noncurrent assets	63	—
Other	16	—
Total extraordinary losses	125	84
Income before income taxes	20,815	12,984
Income taxes-current	5,405	4,290
Income taxes-deferred	580	(337)
Total income taxes	5,985	3,953
Net income	14,829	9,031
Net income attributable to the noncontrolling interest	3,956	988
Net income attributable to owners of the parent	10,873	8,043

(Consolidated Statements of Comprehensive Income)
(For the Six Months Ended September 30, 2023 and 2022)

(Millions of Yen)

	FY2022 (Apr. 1, 2022 – Sept. 30, 2022)	FY2023 (Apr. 1, 2023 – Sept. 30, 2023)
Net income	14,829	9,031
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,113)	4,688
Deferred gains or losses on hedges	372	3
Foreign currency translation adjustment	16,041	12,436
Remeasurements of defined benefit plans	82	111
Total other comprehensive income	15,383	17,240
Comprehensive income	30,213	26,272
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	22,835	23,250
Comprehensive income attributable to noncontrolling interest	7,377	3,022

(3) Consolidated Statements of Cash Flows

(Millions of Yen)

	FY2022 (Apr. 1, 2022 – Sept. 30, 2022)	FY2023 (Apr. 1, 2023 – Sept. 30, 2023)
Net cash provided by (used in) operating activities		
Income before income taxes	20,815	12,984
Depreciation and amortization	4,336	4,796
Amortization of goodwill	472	544
Increase (decrease) in provision	(297)	(231)
Interest and dividends income	(531)	(650)
Interest expenses	149	184
Loss (gain) on sale and retirement of noncurrent assets	(206)	56
Insurance claim income	(652)	—
Decrease (increase) in notes and accounts receivable-trade	(3,541)	941
Decrease (increase) in inventories	(2,429)	1,663
Increase (decrease) in notes and accounts payable-trade	(1,131)	(1,181)
Increase (decrease) in accrued alcohol tax	(116)	3,458
Increase (decrease) in accrued consumption taxes	1,371	(1,639)
Increase (decrease) in other current liabilities	(3,103)	(2,453)
Other, net	203	(702)
Subtotal	15,338	17,771
Interest and dividends income received	541	683
Interest expenses paid	(177)	(213)
Income taxes paid	(9,123)	(3,319)
Proceeds from insurance income	652	—
Net cash provided by (used in) operating activities	7,231	14,922
Net cash provided by (used in) investing activities		
Payments into time deposits	(6,001)	(1,696)
Proceeds from withdrawal of time deposits	1,270	2,596
Purchase of property, plant and equipment and intangible assets	(5,093)	(14,540)
Proceeds from sale of property, plant and equipment and intangible assets	—	(2,160)
Subsidies received	32	—
Other, net	238	2
Net cash provided by (used in) investing activities	(9,553)	(15,796)
Net cash provided by (used in) financing activities		
Proceeds from long-term borrowings	—	456
Redemption of bonds	(10,000)	—
Cash dividends paid	(7,300)	(7,497)
Dividends paid to noncontrolling interests	(1,563)	(1,999)
Repayments of lease obligations	(369)	(492)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	(1,551)	—
Other, net	(840)	(178)
Net cash provided by (used in) financing activities	(21,625)	(9,711)
Effect of exchange rate change on cash and cash equivalents	4,208	3,246
Net increase (decrease) in cash and cash equivalents	(19,738)	(7,339)
Cash and cash equivalents at beginning of period	75,729	91,785
Cash and cash equivalents at end of period	55,991	84,446

(4) Notes to Consolidated Financial Statements**(Notes on Premise of Going Concern)**

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)**I. Equivalent Period of Previous Fiscal Year (From April 1, 2022 to September 30, 2022)****1. Net sales and Income (Loss) by Reported Segment**

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	61,337	63,608	32,584	157,530	6,749	164,279	-	164,279
Intersegment	483	121	2	608	8,827	9,435	(9,435)	-
Total	61,820	63,730	32,587	158,138	15,577	173,715	(9,435)	164,279
Segment income (loss)	2,059	5,658	10,870	18,588	1,243	19,831	(216)	19,614

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(216) million comprises intersegment eliminations of ¥14 million and loss of the Company not allocated to business segments of ¥(231) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2023, to September 30, 2023)**1. Net sales and Income (Loss) by Reported Segment**

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	60,704	76,881	19,116	156,702	6,470	163,172	-	163,172
Intersegment	486	282	0	768	8,396	9,165	(9,165)	-
Total	61,190	77,164	19,116	157,471	14,866	172,338	(9,165)	163,172
Segment income (loss)	3,952	6,256	1,410	11,619	1,193	12,812	(348)	12,464

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business, the transportation business, and the wine import and sale business.

2. The adjustment to segment income (loss) of ¥(348) million comprises intersegment eliminations of ¥(5) million and loss of the Company not allocated to business segments of ¥(343) million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment
No items to report.

(Significant Subsequent Events)

(Acquisition and cancellation of treasury stock)

The meeting of the Company's Board of Directors held on November 9, 2023, approved the acquisition of treasury stock based on the provisions for Article 156 of the Companies Act described in Article 165 (3) of the same act and the cancellation of treasury stock based on the provision of Article 178 of the Companies Act.

1. Reasons for the acquisition and cancellation of treasury stock
The Company will acquire treasury stock in order to execute an agile capital policy that aligns with shareholder returns and the business environment. In conjunction with this, the Company will also cancel treasury stock in accordance with its policy on ownership of treasury stock.
2. Details of acquisition of treasury stock

(1) Classification of stock to be acquired	Common stock of the Company
(2) Number of shares to be acquired	3.0 million shares (upper limit) (1.52% of total number of shares issued and outstanding (excluding treasury stock))
(3) Total cost of acquisition	¥3.0 billion (upper limit)
(4) Period of acquisition	November 13, 2023 to February 20, 2024
(5) Method of acquisition	Open market purchase through the Tokyo Stock Exchange
3. Details of cancellation of treasury stock

(1) Classification of stock to be cancelled	Common stock of the Company
(2) Number of shares to be cancelled	Total number of shares acquired in Item 2 above (1.50% of total number of shares issued and outstanding before cancellation (if 3.0 million shares (upper limit) are acquired))
(3) Scheduled cancellation date	February 29, 2024

2024年3月期
第2四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Second Quarter Ended September 30, 2023

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
 - ① グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)
 - ② 要約貸借対照表
Consolidated Balance Sheets (Summary)
2. 宝酒造
Takara Shuzo
要約損益計算書
Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
要約損益計算書
Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
要約損益計算書
Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 2024年3月期第2四半期 参考資料
Reference Data for the Second Quarter Ended September 30, 2023
7. 2024年3月期 業績予想
Financial forecast for the year ending March 31, 2024
 - ① 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
 - ② 宝酒造
Takara Shuzo
 - ③ 宝酒造インターナショナルグループ
Takara Shuzo International Group
 - ④ タカラバイオグループ
Takara Bio Group
8. 2024年3月期 参考資料
Reference Data for the year ending March 31, 2024

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

広報・IR部 [Public Relations & Investor Relations Dept.](#)

TEL 075(241)5124

FAX 075(241)5127

E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社 広報・IR部

Takara Holdings Inc. Public Relations&Investor Relations Dept.

TEL 075(241)5124 FAX 075(241)5127

E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(注)2024年3月期第2四半期累計期間の業績予想において、
タカラバイオグループのみ2023年8月8日に予想を変更しております。

① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第2四半期累計	2024年3月期 第2四半期累計	実績(c) FY2024(1Q-2Q) Actual (c)	対前期 Change from FY2023(1Q-2Q)		対5/11予想 Change from forecast announced May 2023	
	実績(a) FY2023(1Q-2Q) Actual (a)	5/11予想(b) FY2024(1Q-2Q) Forecast announced May 2023 (b)		増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
宝酒造 Takara Shuzo	61,820	61,621	61,190	△ 629	△1.0%	△ 430	△0.7%
宝酒造インターナショナルグループ Takara Shuzo International Group	63,730	80,017	77,164	13,433	21.1%	△ 2,852	△3.6%
タカラバイオ グループ Takara Bio Group	32,587	19,400	19,116	△ 13,470	△41.3%	△ 283	△1.5%
その他 Other	15,577	15,308	14,866	△ 710	△4.6%	△ 441	△2.9%
調整額 Adjustment	△ 9,435	△ 6,346	△ 9,165	270	—	△ 2,819	—
売上高 Net sales	164,279	170,000	163,172	△ 1,107	△0.7%	△ 6,827	△4.0%
売上原価 Cost of sales	106,400	113,652	107,713	1,312	1.2%	△ 5,938	△5.2%
売上総利益 Gross profit	57,879	57,126	55,459	△ 2,419	△4.2%	△ 1,666	△2.9%
運送費、保管料 Transportation and storage	6,468	6,920	6,556	87	1.4%	△ 363	△5.3%
広告宣伝費 Advertising	1,176	1,474	1,542	366	31.1%	68	4.7%
販売促進費 Sales promotion	1,850	2,723	1,905	55	3.0%	△ 817	△30.0%
研究開発費 Research and development	4,034	4,689	4,428	393	9.7%	△ 260	△5.6%
管理費、その他 Other, net	24,734	30,128	28,562	3,828	15.5%	△ 1,565	△5.2%
販売費及び一般管理費 SG&A expenses	38,264	45,936	42,995	4,730	12.4%	△ 2,940	△6.4%
宝酒造 Takara Shuzo	2,059	2,659	3,952	1,892	91.9%	1,293	48.6%
宝酒造インターナショナルグループ Takara Shuzo International Group	5,658	5,728	6,256	597	10.6%	528	9.2%
タカラバイオ グループ Takara Bio Group	10,870	1,100	1,410	△ 9,460	△87.0%	310	28.2%
その他 Other	1,243	1,135	1,193	△ 49	△4.0%	58	5.1%
調整額 Adjustment	△ 216	478	△ 348	△ 131	—	△ 826	—
営業利益(△:損失) Operating income(△:loss)	19,614	11,100	12,464	△ 7,150	△36.5%	1,364	12.3%
受取利息・配当金 Interest and Dividends income	531	532	650	119	22.4%	118	22.3%
その他営業外収益 Other, net	366	114	397	31	8.6%	283	249.1%
営業外収益 Non-operating income	898	646	1,048	150	16.8%	402	62.3%
支払利息 Interest and discounts expenses	149	196	184	35	23.6%	△ 11	△5.7%
その他営業外費用 Other, net	390	147	295	△ 95	△24.4%	148	100.9%
営業外費用 Non-operating expenses	539	343	480	△ 59	△11.1%	137	39.9%
経常利益(△:損失) Ordinary income(△:loss)	19,972	11,400	13,032	△ 6,940	△34.7%	1,632	14.3%
特別利益 Extraordinary income	967	8	36	△ 931	△96.2%	28	356.7%
特別損失 Extraordinary loss	125	115	84	△ 41	△32.8%	△ 30	△26.8%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	20,815	11,386	12,984	△ 7,830	△37.6%	1,598	14.0%
法人税、住民税及び事業税 Current income taxes	5,405	3,695	4,290	△ 1,114	△20.6%	258	7.0%
法人税等調整額 Deferred income taxes	580		△ 337	△ 918	—		
四半期純利益(△:損失) Net income(△:loss)	14,829	7,690	9,031	△ 5,797	△39.1%	1,341	17.4%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	3,956	958	988	△ 2,968	△75.0%	30	3.2%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	10,873	6,700	8,043	△ 2,829	△26.0%	1,343	20.1%
設備投資額(有形・無形) Capital expenditures	3,513		12,206	8,693	247.4%	12,206	—
減価償却費(有形・無形) Depreciation and Amortization	4,336	4,750	4,796	459	10.6%	46	1.0%
のれん償却額 Amortization of goodwill	472	550	544	71	15.1%	△ 5	△1.1%
営業外収益 Non-operating income	受取利息 153、受取配当金 496 など Interest income 153, Dividends income 496 etc.						
営業外費用 Non-operating expenses	支払利息 184、不動産賃貸費用 46、製品等破損損失 39 など Interest expense 184, Real estate rental costs 46, Damage loss of products 39, etc.						
特別利益 Extraordinary income	固定資産売却益 28 など (前期:受取保険金 652 など) Gain on sale of non-current assets 28 etc. (FY2023:Insurance claim income 652, etc.)						
特別損失 Extraordinary loss	固定資産除売却損 84 (前期:固定資産圧縮損 63 など) Loss on sales and retirement of non-current assets 84 (FY2023: Loss on tax purpose reduction entry of non-current assets 63, etc.)						

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

資産の部 :Assets

(百万円 :Millions of Yen)

	2023年 3月期末 As of Mar. 31, 2023	2024年3月期 第2四半期末 As of Sep. 30, 2023	増減 Change	主な増減理由 Reference
(流動資産) (Total current assets)	241,513	240,349	△ 1,164	(億円 :One hundred millions of Yen)
現金及び預金 Cash and deposits	96,820	89,367	△ 7,453	
受取手形及び売掛金 Notes and accounts receivable-trade	69,717	71,363	1,646	
有価証券 Marketable securities	459	22	△ 436	
棚卸資産 Inventories	66,904	70,712	3,808	
その他 Other current assets	8,305	9,567	1,261	
貸倒引当金 Allowance for doubtful accounts	△ 694	△ 684	10	
(固定資産) (Total fixed assets)	157,661	180,516	22,855	
〔有形固定資産〕 [Property, plant and equipment]	88,890	100,747	11,856	(当期の有形・無形固定資産の主な増減内訳) Reference of Property, plant and equipment and Intangible assets <div> <div>新規取得 TS+7.5、TSI+15.0、TB+98.3 Newly purchases</div> <div>減価償却 TS△12.1、TSI△11.8、TB△21.3 Depreciation</div> </div>
建物及び構築物 Buildings and structures	36,778	38,506	1,727	
機械装置及び運搬具 Machinery, equipment and vehicles	15,265	15,164	△ 101	
土地 Land	20,861	21,507	645	
その他 Other property, plant and equipment	15,985	25,569	9,584	
〔無形固定資産〕 [Intangible fixed assets]	15,931	16,980	1,048	
のれん Goodwill	10,668	11,505	836	
その他 Other intangible fixed assets	5,262	5,474	211	
〔投資その他の資産〕 [Investments and other assets]	52,838	62,789	9,950	
投資有価証券 Investment securities	30,573	37,373	6,799	うち 時価評価 TH +62.4 TS +5.0 Market valuation
その他 Other assets	22,328	25,478	3,149	
貸倒引当金 Allowance for doubtful accounts	△ 64	△ 63	1	
資産合計 Total assets	399,174	420,865	21,691	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

負債及び純資産の部 :Liabilities and net assets

(百万円 :Millions of Yen)

	2023年 3月期末 As of Mar. 31, 2023	2024年3月期 第2四半期末 As of Sep. 30, 2023	増減 Change	主な増減理由 Reference
(流動負債) (Total current liabilities)	67,454	76,847	9,392	(億円 :One hundred millions of Yen)
支払手形及び買掛金 Notes and accounts payable-trade	21,775	22,126	350	
短期借入金 Short-term loans payable	4,919	10,079	5,160	TH +52.0
1年内償還予定の社債 Current portion of bonds payable	—	5,000	5,000	TH +50.0 (第15回普通社債 2024年4月償還) (#15 SB Redemption Apr.2024)
未払酒税 Accrued alcohol tax	5,815	9,274	3,458	
未払費用 Accrued expenses	6,368	6,019	△ 348	
その他 Other current liabilities	28,576	24,347	△ 4,228	
(固定負債) (Total non-current liabilities)	76,401	71,946	△ 4,454	
社債 Bonds payable	20,000	15,000	△ 5,000	TH △50.0 (第15回普通社債 2024年4月償還) (#15 SB Redemption Apr.2024)
長期借入金 Long-term loans payable	15,186	10,482	△ 4,703	TH △51.0
退職給付に係る負債 Net defined benefit liability	8,925	8,872	△ 53	
預り金 Deposits from customers	5,087	5,084	△ 3	
その他 Other non-current liabilities	27,201	32,507	5,306	
負債合計 Total liabilities	143,856	148,794	4,938	
資本金 Capital stock	13,226	13,226	—	
資本剰余金 Capital surplus	1,994	1,994	—	
利益剰余金 Retained earnings	163,825	164,356	530	
自己株式 Treasury stock	△ 1,682	△ 1,682	△ 0	
(株主資本) (Total owner's equity)	177,363	177,893	530	
その他有価証券評価差額金 Valuation difference on available-for-sale securities	12,974	17,663	4,688	TH +43.2
繰延ヘッジ損益 Deferred gains or losses on hedges	286	290	3	
為替換算調整勘定 Translation adjustments	13,686	24,103	10,416	TSI +82.3、TB +21.7
退職給付に係る調整累計額 Remeasurements of defined benefit plans	△ 359	△ 261	97	
(その他の包括利益累計額) (Total valuation and translation adjustments)	26,588	41,795	15,206	
(非支配株主持分) (Noncontrolling interests)	51,366	52,382	1,015	
純資産合計 Total net assets	255,318	272,071	16,753	
負債純資産合計 Total liabilities and net assets	399,174	420,865	21,691	

(TH=Takara Holdings Inc., TS=Takara Shuzo, TSI=Takara Shuzo International Group, TB=Takara Bio Group)

2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

		2023年3月期 第2四半期累計	2024年3月期 第2四半期累計 Apr. 1, 2023 - Sep. 30, 2023		対前期 Change from FY2023(1Q-2Q)		対5/11予想 Change from forecast announced May, 2023	
		実績(a) FY2023(1Q-2Q) Actual (a)	5/11予想(b) FY2024(1Q-2Q) Forecast announced May, 2023 (b)	実績(c) FY2024(1Q-2Q) Actual (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
	焼酎 Shochu	19,998	17,374	17,469	△ 2,528	△ 12.6%	95	0.6%
	清酒 Sake	4,697	4,456	4,252	△ 445	△ 9.5%	△ 203	△ 4.6%
	ソフトアルコール飲料 Light-alcohol refreshers	20,525	21,811	21,782	1,257	6.1%	△ 28	△ 0.1%
	その他酒類 Other liquors	2,823	2,702	2,750	△ 73	△ 2.6%	48	1.8%
	本みりん Hon Mirin	4,710	4,701	4,546	△ 163	△ 3.5%	△ 154	△ 3.3%
	その他調味料 Other seasonings	4,321	4,343	4,447	125	2.9%	104	2.4%
	原料用アルコール等 Raw alcohol	4,743	6,231	5,941	1,197	25.2%	△ 289	△ 4.6%
	売上高 Net sales	61,820	61,621	61,190	△ 629	△ 1.0%	△ 430	△ 0.7%
	売上原価 Cost of sales	47,765	46,304	45,216	△ 2,548	△ 5.3%	△ 1,087	△ 2.3%
	売上総利益 Gross profit	14,055	15,317	15,974	1,918	13.6%	657	4.3%
	運送費、保管料 Transportation and storage	4,029	3,875	3,794	△ 234	△ 5.8%	△ 80	△ 2.1%
	広告宣伝費 Advertising	1,099	1,270	1,355	256	23.3%	85	6.8%
	販売促進費 Sales promotion	1,072	1,647	1,061	△ 10	△ 1.0%	△ 585	△ 35.5%
	研究開発費 Research and development	177	211	182	5	2.8%	△ 28	△ 13.6%
	管理費、その他 Other, net	5,617	5,652	5,627	9	0.2%	△ 24	△ 0.4%
	販売費及び一般管理費 SG&A expenses	11,996	12,658	12,021	25	0.2%	△ 636	△ 5.0%
	営業利益(△:損失) Operating income(△:loss)	2,059	2,659	3,952	1,892	91.9%	1,293	48.6%
	営業外収益 Non-operating income	397	248	283	△ 114	△ 28.7%	35	14.2%
	営業外費用 Non-operating expenses	362	108	134	△ 227	△ 62.8%	26	24.8%
	経常利益(△:損失) Ordinary income(△:loss)	2,094	2,799	4,100	2,006	95.8%	1,301	46.5%
	特別利益 Extraordinary gain	63	8	19	△ 44	△ 69.9%	11	137.8%
	特別損失 Extraordinary loss	94	108	63	△ 30	△ 32.3%	△ 44	△ 41.0%
	税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	2,063	2,699	4,056	1,993	96.6%	1,357	50.3%
	法人税、住民税及び事業税 Current income taxes	761	804	1,239	478	62.8%	429	53.4%
	法人税等調整額 Deferred income taxes	△ 147		△ 6	141	—		
		四半期純利益(△:損失) Net income(△:loss)	1,449	1,895	2,823	1,373	94.8%	928
	設備投資額(有形・無形) Capital expenditures	638		752	113	17.8%	752	—
	減価償却費(有形・無形) Depreciation and Amortization	1,190	1,257	1,217	26	2.3%	△ 39	△ 3.1%

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

	2023年3月期 第2四半期累計 実績(a) FY2023(1Q-2Q) Actual (a)	2024年3月期 第2四半期累計 5/11予想(b) FY2024(1Q-2Q) Forecast announced May, 2023 (b)	実績(c) FY2024(1Q-2Q) Actual (c)	対前期 Change from FY2023(1Q-2Q) 増減(c-a) Change (c-a)		対5/11予想 Change from forecast announced May, 2023 増減(c-b) Change (c-b)	
				率(c/a-1) YOY% (c/a-1)		率(c/b-1) Change% (c/b-1)	
海外酒類事業 Overseas Alcoholic beverages business	8,287	10,096	10,262	1,974	23.8%	166	1.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	56,421	71,216	68,084	11,662	20.7%	△ 3,131	△ 4.4%
その他 Other	2,812	206	215	△ 2,597	△ 92.4%	9	4.4%
連結消去 Elimination	△ 3,791	△ 1,502	△ 1,397	2,394	—	104	—
売上高 Net sales	63,730	80,017	77,164	13,433	21.1%	△ 2,852	△ 3.6%
売上原価 Cost of sales	43,748	55,127	52,786	9,037	20.7%	△ 2,340	△ 4.2%
売上総利益 Gross profit	19,981	24,890	24,377	4,395	22.0%	△ 512	△ 2.1%
運送費、保管料 Transportation and storage	2,253	2,848	2,582	328	14.6%	△ 265	△ 9.3%
広告宣伝費 Advertising	50	86	61	10	21.1%	△ 24	△ 28.3%
販売促進費 Sales promotion	486	603	524	38	7.9%	△ 78	△ 13.0%
管理費、その他 Other, net	11,532	15,623	14,951	3,419	29.7%	△ 671	△ 4.3%
販売費及び一般管理費 SG&A expenses	14,322	19,161	18,120	3,797	26.5%	△ 1,040	△ 5.4%
海外酒類事業 Overseas Alcoholic beverages business	2,466	2,612	2,803	337	13.7%	191	7.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	4,002	4,197	4,713	711	17.8%	516	12.3%
その他 Other	2,232	△ 515	△ 500	△ 2,733	—	14	—
連結消去 Elimination	△ 3,042	△ 565	△ 760	2,282	—	△ 195	—
営業利益(△:損失) Operating income(△:loss)	5,658	5,728	6,256	597	10.6%	528	9.2%
営業外収益 Non-operating income	187	64	199	11	6.2%	135	211.5%
営業外費用 Non-operating expenses	76	141	296	220	288.2%	155	110.3%
経常利益(△:損失) Ordinary income(△:loss)	5,769	5,651	6,159	389	6.8%	508	9.0%
特別利益 Extraordinary gain	0	—	9	8	955.1%	9	—
特別損失 Extraordinary loss	1	—	7	6	471.7%	7	—
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)	5,769	5,650	6,161	391	6.8%	511	9.1%
法人税、住民税及び事業税 Current income taxes	1,709	1,676	1,959	250	14.6%	200	12.0%
法人税等調整額 Deferred income taxes	△ 81		△ 83	△ 2	—		
四半期純利益(△:損失) Net income(△:loss)	4,141	3,973	4,284	143	3.5%	311	7.9%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	585	474	549	△ 35	△ 6.1%	75	15.9%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	3,555	3,498	3,735	179	5.0%	237	6.8%
設備投資額(有形・無形) Capital expenditures	750		1,504	753	100.3%	1,504	—
減価償却費(有形・無形) Depreciation and Amortization	904	1,187	1,189	284	31.5%	1	0.2%
のれん償却額 Amortization of goodwill	192	267	236	44	23.2%	△ 30	△ 11.4%

4. タカラバイオグループ :Takara Bio Group

(注) 2024年3月期第2四半期累計期間の業績予想において、
タカラバイオグループのみ2023年8月8日に予想を変更しております。

要約損益計算書 :Statements of Income (Summary)

(百万円 :Millions of Yen)

		2023年3月期 第2四半期累計	2024年3月期 第2四半期累計 Apr. 1, 2023 - Sep. 30, 2023	対前期 Change from FY2023(1Q-2Q)		対8/8予想 Change from forecast announced Aug. 2023		
		実績(a) FY2023(1Q-2Q)	8/8予想(b) FY2024(1Q-2Q)	実績(c) FY2024(1Q-2Q)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
		Actual (a)	Forecast announced Aug. 2023 (b)	Actual (c)				
試薬 Reagents		27,565	15,083	14,949	△ 12,615	△ 45.8%	△ 133	△ 0.9%
機器 Instruments		694	492	411	△ 282	△ 40.7%	△ 80	△ 16.3%
受託 CDMO		3,183	2,749	2,702	△ 480	△ 15.1%	△ 46	△ 1.7%
遺伝子医療 Gene Therapy		1,144	1,074	1,052	△ 91	△ 8.0%	△ 21	△ 2.0%
売上高 Net sales		32,587	19,400	19,116	△ 13,470	△ 41.3%	△ 283	△ 1.5%
売上原価 Cost of sales		10,562	5,928	5,772	△ 4,789	△ 45.3%	△ 155	△ 2.6%
売上総利益 Gross profit		22,025	13,471	13,343	△ 8,681	△ 39.4%	△ 127	△ 0.9%
運送費、保管料 Transportation and storage		330	300	285	△ 45	△ 13.7%	△ 14	△ 4.9%
広告宣伝費 Advertising		21	30	32	10	48.8%	2	8.5%
販売促進費 Sales promotion		306	330	347	40	13.3%	17	5.4%
研究開発費 Research and development		3,853	4,498	4,241	387	10.1%	△ 256	△ 5.7%
管理費、その他 Other, net		6,641	7,213	7,026	384	5.8%	△ 186	△ 2.6%
販売費及び一般管理費 SG&A expenses		11,154	12,371	11,933	778	7.0%	△ 437	△ 3.5%
営業利益(△:損失) Operating income(△:loss)		10,870	1,100	1,410	△ 9,460	△ 87.0%	310	28.2%
営業外収益 Non-operating income		170	154	248	77	45.5%	94	61.4%
営業外費用 Non-operating expenses		85	84	59	△ 25	△ 29.7%	△ 24	△ 28.7%
経常利益(△:損失) Ordinary income(△:loss)		10,955	1,170	1,598	△ 9,356	△ 85.4%	428	36.7%
特別利益 Extraordinary income		902	1	1	△ 901	△ 99.8%	0	79.1%
特別損失 Extraordinary loss		27	9	12	△ 14	△ 54.4%	3	37.3%
税金等調整前四半期純利益(△:損失) Income before income taxes(△:loss)		11,831	1,162	1,588	△ 10,243	△ 86.6%	426	36.7%
法人税、住民税及び事業税 Current income taxes		2,538	497	684	△ 1,854	△ 73.0%	△ 7	△ 1.5%
法人税等調整額 Deferred income taxes		721		△ 195	△ 916	—		
四半期純利益(△:損失) Net income(△:loss)		8,572	664	1,099	△ 7,473	△ 87.2%	435	65.5%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)		33	14	14	△ 18	△ 55.7%	0	6.5%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(△:loss)		8,538	650	1,084	△ 7,454	△ 87.3%	434	66.8%
設備投資額(有形・無形) Capital expenditures		2,056		9,832	7,775	378.1%	9,832	—
減価償却費(有形・無形) Depreciation and Amortization		1,962	2,206	2,132	170	8.7%	△ 73	△ 3.3%
のれん償却額 Amortization of goodwill		280	307	307	26	9.6%	0	0.1%

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	2024年3月期 第2四半期 FY2024 (1Q-2Q)	前期対比 Change from FY2023(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	133,987	137,502	127,784	141,213	164,279	163,172	△ 1,107	△ 0.7%
売上原価 Cost of sales	81,332	84,468	76,361	86,872	106,400	107,713	1,312	1.2%
(売上高原価率) (Ratio to Net sales)	60.7%	61.4%	59.8%	61.5%	64.8%	66.0%	+1.2pt	1.9%
売上総利益 Gross profit	52,655	53,033	51,422	54,340	57,879	55,459	△ 2,419	△ 4.2%
販売費及び一般管理費 SG&A expenses	44,495	45,410	45,639	32,724	38,264	42,995	4,730	12.4%
(売上高販管費率) (Ratio to Net sales)	33.2%	33.0%	35.7%	23.2%	23.3%	26.3%	+3.1pt	13.1%
営業利益(△:損失) Operating income(Δ:loss)	8,159	7,623	5,782	21,616	19,614	12,464	△ 7,150	△ 36.5%
(売上高営業利益率) (Ratio to Net Sales)	6.1%	5.5%	4.5%	15.3%	11.9%	7.6%	-4.3pt	△ 36.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	16,459	17,011	16,885	1,697	1,850	1,905	55	3.0%
(売上高販促費率) (Ratio to Net sales)	12.3%	12.4%	13.2%	1.2%	1.1%	1.2%	+0.0pt	3.7%
研究開発費 R&D expenses	2,286	2,057	2,579	2,847	4,034	4,428	393	9.7%
(売上高研究開発費率) (Ratio to Net sales)	1.7%	1.5%	2.0%	2.0%	2.5%	2.7%	+0.3pt	10.5%
設備投資額(有形・無形) Capital expenditures	2,603	8,421	8,448	8,811	3,513	12,206	8,693	247.4%
減価償却費(有形・無形) Depreciation and Amortization	3,183	3,364	3,997	4,061	4,336	4,796	459	10.6%
のれん償却額 Amortization of goodwill	429	424	432	432	472	544	71	15.1%

※2022年3月期より、収益認識に関する会計基準等の適用に伴い、従来販売費及び一般管理費で処理していた費用の一部を売上高から控除しております。

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	2024年3月期 第2四半期 FY2024 (1Q-2Q)	前期対比 Change from FY2023(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	73,259	75,135	74,164	57,633	61,820	61,190	△ 629	△ 1.0%
売上原価 Cost of sales	44,144	45,586	45,183	43,341	47,765	45,216	△ 2,548	△ 5.3%
(売上高原価率) (Ratio to Net sales)	60.3%	60.7%	60.9%	75.2%	77.3%	73.9%	-3.4pt	△ 4.4%
売上総利益 Gross profit	29,115	29,549	28,981	14,291	14,055	15,974	1,918	13.6%
販売費及び一般管理費 SG&A expenses	26,839	27,467	27,355	12,020	11,996	12,021	25	0.2%
(売上高販管費率) (Ratio to Net sales)	36.6%	36.6%	36.9%	20.9%	19.4%	19.6%	+0.2pt	1.2%
営業利益(△:損失) Operating income(Δ:loss)	2,275	2,082	1,626	2,270	2,059	3,952	1,892	91.9%
(売上高営業利益率) (Ratio to Net sales)	3.1%	2.8%	2.2%	3.9%	3.3%	6.5%	+3.1pt	93.9%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	15,845	16,431	16,429	1,059	1,072	1,061	△ 10	△ 1.0%
(売上高販促費率) (Ratio to Net sales)	21.6%	21.9%	22.2%	1.8%	1.7%	1.7%	+0.0pt	0.0%
設備投資額(有形・無形) Capital expenditures	799	4,004	477	500	638	752	113	17.8%
減価償却費(有形・無形) Depreciation and Amortization	1,080	1,165	1,397	1,257	1,190	1,217	26	2.3%

※2022年3月期より、収益認識に関する会計基準等の適用に伴い、従来販売費及び一般管理費で処理していた費用の一部を売上高から控除しております。

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	2024年3月期 第2四半期 FY2024 (1Q-2Q)	前期対比 Change from FY2023(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	37,527	40,477	31,286	46,734	63,730	77,164	13,433	21.1%
売上原価 Cost of sales	26,329	28,994	22,140	31,747	43,748	52,786	9,037	20.7%
(売上高原価率) (Ratio to Net sales)	70.2%	71.6%	70.8%	67.9%	68.6%	68.4%	-0.2pt	△ 0.3%
売上総利益 Gross profit	11,197	11,483	9,145	14,987	19,981	24,377	4,395	22.0%
販売費及び一般管理費 SG&A expenses	8,762	9,918	9,541	10,682	14,322	18,120	3,797	26.5%
(売上高販管費率) (Ratio to Net sales)	23.3%	24.5%	30.5%	22.9%	22.5%	23.5%	+1.0pt	4.5%
営業利益(△:損失) Operating income(Δ:loss)	2,434	1,565	△ 396	4,304	5,658	6,256	597	10.6%
(売上高営業利益率) (Ratio to Net sales)	6.5%	3.9%	—	9.2%	8.9%	8.1%	-0.8pt	△ 8.7%
設備投資額(有形・無形) Capital expenditures	614	908	1,631	462	750	1,504	753	100.3%
減価償却費(有形・無形) Depreciation and Amortization	496	585	696	837	904	1,189	284	31.5%
のれん償却額 Amortization of goodwill	182	173	186	187	192	236	44	23.2%

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2019年3月期 第2四半期 FY2019 (1Q-2Q)	2020年3月期 第2四半期 FY2020 (1Q-2Q)	2021年3月期 第2四半期 FY2021 (1Q-2Q)	2022年3月期 第2四半期 FY2022 (1Q-2Q)	2023年3月期 第2四半期 FY2023 (1Q-2Q)	2024年3月期 第2四半期 FY2024 (1Q-2Q)	前期対比 Change from FY2023(1Q-2Q)	
							増減 Change	率 YOY%
売上高 Net sales	17,370	16,450	17,393	31,551	32,587	19,116	△ 13,470	△ 41.3%
売上原価 Cost of sales	7,049	6,121	5,565	8,056	10,562	5,772	△ 4,789	△ 45.3%
(売上高原価率) (Ratio to Net sales)	40.6%	37.2%	32.0%	25.5%	32.4%	30.2%	-2.2pt	△ 6.8%
売上総利益 Gross profit	10,321	10,329	11,827	23,495	22,025	13,343	△ 8,681	△ 39.4%
販売費及び一般管理費 SG&A expenses	7,697	7,293	8,090	9,389	11,154	11,933	778	7.0%
(売上高販管費率) (Ratio to Net sales)	44.3%	44.3%	46.5%	29.8%	34.2%	62.4%	+28.2pt	82.4%
営業利益(△:損失) Operating income(Δ:loss)	2,623	3,035	3,736	14,105	10,870	1,410	△ 9,460	△ 87.0%
(売上高営業利益率) (Ratio to Net sales)	15.1%	18.5%	21.5%	44.7%	33.4%	7.4%	-26.0pt	△ 77.9%
研究開発費 R&D expenses	2,104	1,858	2,403	2,659	3,853	4,241	387	10.1%
(売上高研究開発費率) (Ratio to Net sales)	12.1%	11.3%	13.8%	8.4%	11.8%	22.2%	+10.4pt	87.6%
設備投資額(有形・無形) Capital expenditures	1,068	3,190	6,087	7,676	2,056	9,832	7,775	378.1%
減価償却費(有形・無形) Depreciation and Amortization	1,336	1,352	1,631	1,670	1,962	2,132	170	8.7%
のれん償却額 Amortization of goodwill	247	250	246	245	280	307	26	9.6%

6. 2024年3月期第2四半期 参考資料 :Reference Data for the Second Quarter Ended September 30, 2023

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

	2023年3月期 第2四半期累計	2024年3月期 第2四半期累計 Apr. 1, 2023 - Sep. 30, 2023	
	実績(a) FY2023(1Q-2Q) Actual (a)	実績(b) FY2024(1Q-2Q) Actual (b)	前期差(b-a) Change(b-a)
米ドル : US dollar	123.15	134.99	11.84
ポンド: Pound	159.58	166.61	7.03
ユーロ: Euro	134.39	145.92	11.53
人民元: Yuan	18.97	19.45	0.48
100ウォン: 100 Won	9.97	10.43	0.46
インドルピー: Rupee	1.62	1.64	0.02
オーストラリアドル :Australian dollar	88.52	91.22	2.70

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

	対前期 Change from FY2023(1Q-2Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	6,711
宝酒造インターナショナルグループ 計 Net sales of Takara Shuzo International Group	5,851
海外酒類事業 Overseas Alcoholic beverages business	727
海外日本食材卸事業 Japanese food wholesale business in overseas markets	5,243
その他および調整額 Other / Adjustment	△ 118
タカラバイオグループ 計 Net sales of Takara Bio Group	859
試薬 Reagents	761
機器 Instruments	11
受託 CDMO	6
遺伝子医療 Gene Therapy	79

② 海外売上高比率の推移 :Change in overseas sales ratio

	2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual			2024年3月期第2四半期 実績 FY2024(1Q-2Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	61,820	—	—	61,190	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	63,730	63,455	99.6%	77,164	76,606	99.2%
タカラバイオグループ Takara Bio Group	32,587	16,288	49.9%	19,116	12,818	67.0%
その他および調整額 Other / Adjustment	6,141	—	—	5,701	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	164,279	79,744	48.5%	163,172	89,424	54.8%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual		2024年3月期第2四半期 実績 FY2024(1Q-2Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ド ル :Thousands of US dollar	23,744	3,133	23,459	2,704
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,924	385	3,166	365
宝酒造食品 (中国)	千 元 :Thousands of Yuan	17,653	Δ 1,359	22,800	Δ 1,205
Takara Shuzo Foods Co.,Ltd. (China)	百 万 円 :Millions of Yen	334	Δ 25	443	Δ 23
トマーチン (英国)	千 ボ ン ド :Thousands of Pound	14,130	4,865	15,297	4,513
The Tomatin Distillery Co.,Ltd (U.K.)	百 万 円 :Millions of Yen	2,254	776	2,548	752
エイジ・インターナショナル (米国)	千 US ド ル :Thousands of US dollar	20,034	9,129	27,930	12,839
AGE INTERNATIONAL,INC. (U.S.)	百 万 円 :Millions of Yen	2,467	1,124	3,770	1,733
フーデックスグループ (欧州)	千 ユ ー ロ :Thousands of Euro	128,891	12,549	135,647	10,657
FOODEX Group (Europe)	百 万 円 :Millions of Yen	17,321	1,686	19,793	1,555
タザキフーズ (英国)	千 ボ ン ド :Thousands of Pound	33,353	777	38,021	2,232
TAZAKI FOODS LTD. (U.K.)	百 万 円 :Millions of Yen	5,322	124	6,334	371
ミューチャルトレーディング (米国)	千 US ド ル :Thousands of US dollar	244,174	14,151	281,144	16,467
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	30,070	1,742	37,951	2,222
ニッポンフード (豪州)	千 AUS ド ル :Thousands of Australian dollar	29,689	2,151	32,079	2,204
Nippon Food Supplies Company Pty Ltd (Austraria)	百 万 円 :Millions of Yen	2,628	190	2,926	201
東京共同貿易 Tokyo Mutual Trading Co., Ltd	百 万 円 :Millions of Yen	7,522	445	7,083	381
タカラバイオヨーロッパS.A.S. 連結	千 ユ ー ロ :Thousands of Euro	18,165	1,896	15,596	Δ 1,206
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	2,441	254	2,275	Δ 175
宝生物工程(大連)	千 元 :Thousands of Yuan	149,280	47,310	79,915	3,142
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	2,831	897	1,554	61
宝日医生物技術(北京)	千 元 :Thousands of Yuan	283,742	45,843	153,283	10,242
Takara Biomedical Technology (Beijing) Co., Ltd.	百 万 円 :Millions of Yen	5,382	869	2,981	199
タカラコリアバイオメディカル	百 万 ウ ォ ン :Millions of Won	7,327	1,128	7,020	1,150
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	730	112	732	119
タカラバイオDSSインド	千 イ ン ト ル ビ ー :Thousands of Rupee	451,130	50,563	194,817	18,689
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	730	81	319	30
タカラバイオUSA	千 US ド ル :Thousands of US dollar	69,965	15,137	56,550	1,822
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,616	1,864	7,633	245

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo
(百万円 :Millions of Yen)

	対前期増減 Change from FY2023(1Q-2Q)		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+1,918	Δ 143	+2,061
(参考) 原価コストダウン Reference :Cost reduction	Δ 1,790 ※上記構成差に含む *Included in change in sales composition		

※利益の増加要因を「+」、減少要因を「Δ」で表示
*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結) 要約損益計算書(p.1)における「その他」の内訳
Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

		2023年3月期第2四半期 実績 FY2023(1Q-2Q) Actual		2024年3月期第2四半期 実績 FY2024(1Q-2Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
ワイン輸入販売事業 Import and sale of wine		2,800	582	2,717	627
物流事業 Transportation		6,897	314	6,507	237
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)		249	206	252	208
その他 Other		5,629	139	5,389	118
「その他」計 Total "Other"		15,577	1,243	14,866	1,193

7. 2024年3月期 業績予想 :Financial forecast for the year ending March 31, 2024

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2023年3月期 FY2023	2024年3月期 FY2024_Apr. 1, 2023 - Mar. 31, 2024		対前期 Change from FY2023		対5/11予想 Change from forecast announced May, 2023	
	実績(a) Actual (a)	5/11予想(b) Forecast announced May, 2023 (b)	11/9予想(c) Forecast announced Nov. 2023 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
宝酒造 Takara Shuzo	122,921	123,526	122,467	△ 454	△ 0.4%	△ 1,059	△ 0.9%
宝酒造インターナショナルグループ Takara Shuzo International Group	137,483	165,700	161,400	23,916	17.4%	△ 4,300	△ 2.6%
タカラバイオ グループ Takara Bio Group	78,142	53,300	45,500	△ 32,642	△ 41.8%	△ 7,800	△ 14.6%
その他 Other	30,950	31,215	30,430	△ 520	△ 1.7%	△ 785	△ 2.5%
調整額 Adjustment	△ 18,832	△ 18,741	△ 18,797	35	—	△ 56	—
売上高 Net sales	350,665	355,000	341,000	△ 9,665	△ 2.8%	△ 14,000	△ 3.9%
売上原価 Cost of sales	230,723	234,100	226,600	△ 4,123	△ 1.8%	△ 7,500	△ 3.2%
売上総利益 Gross profit	119,941	120,900	114,400	△ 5,541	△ 4.6%	△ 6,500	△ 5.4%
運送費、保管料 Transportation and storage	13,119	14,200	13,600	480	3.7%	△ 600	△ 4.2%
広告宣伝費 Advertising	2,840	3,400	4,000	1,159	40.8%	600	17.6%
販売促進費 Sales promotion	4,220	6,300	5,000	779	18.5%	△ 1,300	△ 20.6%
研究開発費 Research and development	8,949	9,400	9,200	250	2.8%	△ 200	△ 2.1%
管理費、その他 Other, net	52,866	61,300	60,900	8,033	15.2%	△ 400	△ 0.7%
販売費及び一般管理費 SG&A expenses	81,996	94,600	92,700	10,703	13.1%	△ 1,900	△ 2.0%
宝酒造 Takara Shuzo	4,890	4,541	5,327	436	8.9%	786	17.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	10,821	12,500	12,200	1,378	12.7%	△ 300	△ 2.4%
タカラバイオ グループ Takara Bio Group	20,541	8,000	3,000	△ 17,541	△ 85.4%	△ 5,000	△ 62.5%
その他 Other	2,293	2,327	2,371	77	3.4%	44	1.9%
調整額 Adjustment	△ 601	△ 1,068	△ 1,198	△ 596	—	△ 130	—
営業利益(△:損失) Operating income(△:loss)	37,945	26,300	21,700	△ 16,245	△ 42.8%	△ 4,600	△ 17.5%
受取利息・配当金 Interest and Dividends income	1,066	1,000	1,300	233	21.9%	300	30.0%
その他営業外収益 Other, net	612	400	600	△ 12	△ 2.0%	200	50.0%
営業外収益 Non-operating income	1,678	1,400	1,900	221	13.2%	500	35.7%
支払利息 Interest and discounts expenses	324	450	450	125	38.5%	—	—
その他営業外費用 Other, net	593	450	650	56	9.6%	200	44.4%
営業外費用 Non-operating expenses	917	900	1,100	182	19.8%	200	22.2%
経常利益(△:損失) Ordinary income(△:loss)	38,706	26,800	22,500	△ 16,206	△ 41.9%	△ 4,300	△ 16.0%
特別利益 Extraordinary income	1,681	8	2,770	1,088	64.8%	2,762	—
特別損失 Extraordinary loss	694	508	670	△ 24	△ 3.6%	162	31.9%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	39,692	26,300	24,600	△ 15,092	△ 38.0%	△ 1,700	△ 6.5%
法人税、住民税及び事業税 Current income taxes	10,144	8,200	7,800	△ 3,201	△ 29.1%	△ 400	△ 4.9%
法人税等調整額 Deferred income taxes	857						
当期純利益(△:損失) Net income(△:loss)	28,690	18,100	16,800	△ 11,890	△ 41.4%	△ 1,300	△ 7.2%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	7,483	3,100	1,800	△ 5,683	△ 75.9%	△ 1,300	△ 41.9%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	21,206	15,000	15,000	△ 6,206	△ 29.3%	—	—
設備投資額(有形・無形) Capital expenditures	14,165	24,307	24,307	10,142	71.6%	—	—
減価償却費(有形・無形) Depreciation and Amortization	9,118	10,200	10,100	981	10.8%	△ 100	△ 1.0%
のれん償却額 Amortization of goodwill	998	1,100	1,300	301	30.2%	200	18.2%

② 宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

	2023年3月期 FY2023	2024年3月期 FY2024_Apr. 1, 2023 - Mar. 31, 2024		対前期 Change from FY2023		対5/11予想 Change from forecast announced May. 2023	
	実績(a) Actual (a)	5/11予想(b) Forecast announced May. 2023 (b)	11/9予想(c) Forecast announced Nov. 2023 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
焼酎 Shochu	36,597	33,401	33,655	△ 2,942	△ 8.0%	254	0.8%
清酒 Sake	12,145	11,518	11,358	△ 787	△ 6.5%	△ 160	△ 1.4%
ソフトアルコール飲料 Light-alcohol refreshers	40,069	42,391	42,401	2,331	5.8%	10	0.0%
その他酒類 Other liquors	5,328	5,039	5,410	81	1.5%	371	7.4%
本みりん Hon Mirin	9,477	9,697	9,110	△ 367	△ 3.9%	△ 587	△ 6.1%
その他調味料 Other seasonings	8,780	8,860	9,186	405	4.6%	326	3.7%
原料用アルコール等 Raw alcohol	10,522	12,618	11,344	821	7.8%	△ 1,274	△ 10.1%
売上高 Net sales	122,921	123,526	122,467	△ 454	△ 0.4%	△ 1,059	△ 0.9%
売上原価 Cost of sales	93,645	92,389	91,201	△ 2,444	△ 2.6%	△ 1,188	△ 1.3%
売上総利益 Gross profit	29,276	31,137	31,266	1,989	6.8%	129	0.4%
運送費、保管料 Transportation and storage	7,857	8,036	7,879	21	0.3%	△ 157	△ 2.0%
広告宣伝費 Advertising	2,626	2,975	3,589	962	36.7%	614	20.6%
販売促進費 Sales promotion	2,457	3,988	2,930	472	19.2%	△ 1,058	△ 26.5%
研究開発費 Research and development	367	429	390	22	6.1%	△ 39	△ 9.1%
管理費、その他 Other, net	11,076	11,168	11,151	74	0.7%	△ 17	△ 0.2%
販売費及び一般管理費 SG&A expenses	24,385	26,596	25,939	1,553	6.4%	△ 657	△ 2.5%
営業利益(△:損失) Operating income(△:loss)	4,890	4,541	5,327	436	8.9%	786	17.3%
営業外収益 Non-operating income	544	317	354	△ 190	△ 35.0%	37	11.7%
営業外費用 Non-operating expenses	567	230	247	△ 320	△ 56.5%	17	7.4%
経常利益(△:損失) Ordinary income(△:loss)	4,867	4,628	5,434	566	11.6%	806	17.4%
特別利益 Extraordinary gain	63	8	19	△ 44	△ 69.9%	11	137.5%
特別損失 Extraordinary loss	234	416	552	317	135.1%	136	32.7%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	4,696	4,220	4,901	204	4.4%	681	16.1%
法人税、住民税及び事業税 Current income taxes	1,277	1,305	1,522	63	4.4%	217	16.6%
法人税等調整額 Deferred income taxes	181						
当期純利益(△:損失) Net income(△:loss)	3,237	2,915	3,379	141	4.4%	464	15.9%
設備投資額(有形・無形) Capital expenditures	2,763	4,774	4,774	2,010	72.7%	—	—
減価償却費(有形・無形) Depreciation and Amortization	2,467	2,684	2,604	136	5.5%	△ 80	△ 3.0%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

	2023年3月期 FY2023	2024年3月期 FY2024_Apr. 1, 2023 - Mar. 31, 2024		対前期 Change from FY2023		対5/11予想 Change from forecast announced May. 2023	
	実績(a) Actual (a)	5/11予想(b) Forecast announced May. 2023 (b)	11/9予想(c) Forecast announced Nov. 2023 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
海外酒類事業 Overseas Alcoholic beverages business	18,253	21,106	21,161	2,907	15.9%	55	0.3%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	121,354	147,207	142,730	21,375	17.6%	△ 4,477	△ 3.0%
その他 Other	2,847	247	247	△ 2,600	△ 91.3%	—	—
連結消去 Elimination	△ 4,972	△ 2,861	△ 2,740	2,232	—	121	—
売上高 Net sales	137,483	165,700	161,400	23,916	17.4%	△ 4,300	△ 2.6%
売上原価 Cost of sales	95,088	113,505	109,940	14,851	15.6%	△ 3,565	△ 3.1%
売上総利益 Gross profit	42,394	52,195	51,460	9,065	21.4%	△ 735	△ 1.4%
運送費、保管料 Transportation and storage	4,883	5,859	5,448	564	11.6%	△ 411	△ 7.0%
広告宣伝費 Advertising	136	193	152	15	11.5%	△ 41	△ 21.2%
販売促進費 Sales promotion	1,109	1,368	1,326	216	19.5%	△ 42	△ 3.1%
管理費、その他 Other, net	25,443	32,275	32,334	6,890	27.1%	59	0.2%
販売費及び一般管理費 SG&A expenses	31,573	39,695	39,260	7,686	24.3%	△ 435	△ 1.1%
海外酒類事業 Overseas Alcoholic beverages business	4,895	5,860	5,861	965	19.7%	1	0.0%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	7,559	8,837	8,764	1,204	15.9%	△ 73	△ 0.8%
その他 Other	1,700	△ 1,320	△ 1,186	△ 2,886	—	134	—
連結消去 Elimination	△ 3,334	△ 877	△ 1,239	2,095	—	△ 362	—
営業利益(△:損失) Operating income(△:loss)	10,821	12,500	12,200	1,378	12.7%	△ 300	△ 2.4%
営業外収益 Non-operating income	315	166	436	120	38.1%	270	162.7%
営業外費用 Non-operating expenses	169	337	575	405	239.0%	238	70.6%
経常利益(△:損失) Ordinary income(△:loss)	10,967	12,329	12,061	1,093	10.0%	△ 268	△ 2.2%
特別利益 Extraordinary gain	8	—	25	16	194.0%	25	—
特別損失 Extraordinary loss	68	38	50	△ 18	△ 26.9%	12	31.6%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	10,907	12,291	12,036	1,128	10.3%	△ 255	△ 2.1%
法人税等 Current income taxes, etc.	3,255	3,540	3,618	333	10.2%	78	2.2%
法人税等調整額 Deferred income taxes	28						
当期純利益(△:損失) Net income(△:loss)	7,623	8,751	8,418	794	10.4%	△ 333	△ 3.8%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	1,189	984	1,021	△ 168	△ 14.1%	37	3.8%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	6,434	7,767	7,397	962	15.0%	△ 370	△ 4.8%
設備投資額(有形・無形) Capital expenditures	4,704	3,187	3,187	△ 1,517	△ 32.3%	—	—
減価償却費(有形・無形) Depreciation and Amortization	2,043	2,416	2,439	395	19.4%	23	1.0%
のれん償却額 Amortization of goodwill	399	534	701	301	75.6%	167	31.3%

④ タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

	2023年3月期 FY2023	2024年3月期 FY2024_Apr. 1, 2023 - Mar. 31, 2024		対前期 Change from FY2023		対5/11予想 Change from forecast announced May. 2023	
	実績(a) Actual (a)	5/11予想(b) Forecast announced May. 2023 (b)	11/9予想(c) Forecast announced Nov. 2023 (c)	増減(c-a) Change (c-a)	率(c/a-1) YOY% (c/a-1)	増減(c-b) Change (c-b)	率(c/b-1) Change% (c/b-1)
試薬 Reagents	65,925	38,353	32,792	△ 33,133	△ 50.3%	△ 5,560	△ 14.5%
機器 Instruments	1,375	2,019	1,314	△ 61	△ 4.5%	△ 704	△ 34.9%
受託 CDMO	8,200	9,914	8,652	451	5.5%	△ 1,261	△ 12.7%
遺伝子医療 Gene Therapy	2,640	3,012	2,740	100	3.8%	△ 271	△ 9.0%
売上高 Net sales	78,142	53,300	45,500	△ 32,642	△ 41.8%	△ 7,800	△ 14.6%
売上原価 Cost of sales	33,377	19,315	17,399	△ 15,978	△ 47.9%	△ 1,916	△ 9.9%
売上総利益 Gross profit	44,765	33,984	28,100	△ 16,665	△ 37.2%	△ 5,884	△ 17.3%
運送費、保管料 Transportation and storage	653	691	638	△ 15	△ 2.3%	△ 53	△ 7.7%
広告宣伝費 Advertising	48	74	70	21	44.2%	△ 4	△ 5.4%
販売促進費 Sales promotion	699	965	796	96	13.8%	△ 169	△ 17.5%
研究開発費 Research and development	8,575	9,000	8,810	234	2.7%	△ 190	△ 2.1%
管理費、その他 Other, net	14,247	15,253	14,785	537	3.8%	△ 468	△ 3.1%
販売費及び一般管理費 SG&A expenses	24,224	25,984	25,100	875	3.6%	△ 884	△ 3.4%
営業利益(△:損失) Operating income(△:loss)	20,541	8,000	3,000	△ 17,541	△ 85.4%	△ 5,000	△ 62.5%
営業外収益 Non-operating income	363	386	394	30	8.5%	8	2.1%
営業外費用 Non-operating expenses	221	186	194	△ 27	△ 12.5%	8	4.3%
経常利益(△:損失) Ordinary income(△:loss)	20,682	8,200	3,200	△ 17,482	△ 84.5%	△ 5,000	△ 61.0%
特別利益 Extraordinary income	930	—	1	△ 929	△ 99.9%	1	—
特別損失 Extraordinary loss	388	59	60	△ 328	△ 84.6%	1	1.7%
税金等調整前当期純利益(△:損失) Income before income taxes(△:loss)	21,224	8,140	3,140	△ 18,084	△ 85.2%	△ 5,000	△ 61.4%
法人税、住民税及び事業税 Current income taxes	4,679	2,612	1,110	△ 4,066	△ 78.6%	△ 1,502	△ 57.5%
法人税等調整額 Deferred income taxes	496						
当期純利益(△:損失) Net income(△:loss)	16,047	5,528	2,030	△ 14,017	△ 87.4%	△ 3,498	△ 63.3%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(△:loss)	35	28	30	△ 5	△ 16.2%	2	7.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(△:loss)	16,012	5,500	2,000	△ 14,012	△ 87.5%	△ 3,500	△ 63.6%
設備投資額(有形・無形) Capital expenditures	6,516	16,024	16,024	9,508	145.9%	—	—
減価償却費(有形・無形) Depreciation and Amortization	4,050	4,590	4,552	501	12.4%	△ 38	△ 0.8%
のれん償却額 Amortization of goodwill	599	637	635	35	6.0%	△ 2	△ 0.3%

8. 2024年3月期 参考資料 :Reference Data for the year ending March 31, 2024

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of overseas subsidiaries

(円 : Yen)

	2023年3月期 FY2023	2024年3月期 FY2024_Apr. 1, 2023 - Mar. 31, 2024			
	実績(a) Actual (a)	5/11予想(b) Forecast announced May, 2023 (b)	11/9予想(c) Forecast announced Nov. 2023 (c)	前期差(c-a) Change(c-a)	予想差(c-b) Change(c-b)
米ドル : US dollar	131.64	140.00	139.60	7.96	△ 0.40
ポンド: Pound	162.02	162.00	173.90	11.88	11.90
ユーロ: Euro	138.15	141.00	151.00	12.85	10.00
人民元: Yuan	19.50	19.50	19.70	0.20	0.20
100ウォン: 100 Won	10.18	10.10	10.70	0.52	0.60
インドルピー: Rupee	1.67	1.70	1.70	0.03	0.00
オーストラリアドル :Australian dollar	91.13	91.70	92.50	1.37	0.80

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2023
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	11,444
うち宝酒造インターナショナルグループ Net sales of Takara Shuzo International Group	10,087
海外酒類事業 Overseas Alcoholic beverages business	1,182
海外日本食材卸事業 Japanese food wholesale business in overseas markets	9,060
その他および調整額 Other / Adjustment	△ 154
うちタカラバイオグループ Net sales of Takara Bio Group	1,356
試薬 Reagents	1,164
機器 Instruments	28
受託 CDMO	7
遺伝子医療 Gene Therapy	155

② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

	2023年3月期通期 実績 FY2023 Actual			2024年3月期通期 予想 FY2024 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	122,921	—	—	122,467	—	—
宝酒造インターナショナルグループ Takara Shuzo International Group	137,483	136,900	99.6%	161,400	160,646	99.5%
タカラバイオグループ Takara Bio Group	78,142	32,475	41.6%	45,500	28,063	61.6%
その他および調整額 Other / Adjustment	12,117	—	—	11,633	—	—
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	350,665	169,375	48.3%	341,000	188,709	55.3%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2023年3月期通期 実績		2024年3月期通期 予想	
		FY2023 Actual		FY2024 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ/loss)	売上高 Net Sales	営業利益 Operating income(Δ/loss)
米国宝酒造	千 US ドル :Thousands of US dollar	46,041	5,007	46,187	5,309
Takara Sake USA Inc.	百 万 円 :Millions of Yen	6,060	659	6,447	741
宝酒造食品 (中国)	千 元 :Thousands of Yuan	40,858	Δ 4,194	49,666	Δ 2,470
Takara Shuzo Foods Co.,Ltd. (China)	百 万 円 :Millions of Yen	796	Δ 81	978	Δ 48
トマーチン (英国)	千 ポンド :Thousands of Pound	31,190	11,191	35,165	12,463
The Tomatin Distillery Co.,Ltd (U.K.)	百 万 円 :Millions of Yen	5,053	1,813	6,115	2,167
エイジ・インターナショナル (米国)	千 US ドル :Thousands of US dollar	43,445	20,330	48,255	21,670
AGE INTERNATIONAL,INC. (U.S.)	百 万 円 :Millions of Yen	5,719	2,676	6,736	3,025
フーデックス7社連結 (欧州)	千 ユーロ :Thousands of Euro	182,053	11,684	181,423	9,834
FOODEX Group (Europe)	百 万 円 :Millions of Yen	25,150	1,614	27,394	1,484
コミンポート・ケタフーズ (欧州)	千 ユーロ :Thousands of Euro	89,265	7,428	99,744	10,017
Cominport Distribución S.L., Keta Foods, Lda (Europe)	百 万 円 :Millions of Yen	12,332	1,026	15,061	1,512
タザキフーズ (英国)	千 ポンド :Thousands of Pound	69,068	1,602	74,000	3,700
TAZAKI FOODS LTD. (U.K.)	百 万 円 :Millions of Yen	11,190	259	12,868	643
ミューチャルトレーディング (米国)	千 US ドル :Thousands of US dollar	499,304	27,344	570,943	29,100
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	65,728	3,599	79,703	4,062
ニッポンフード (豪州)	千 AUS ドル :Thousands of Australian dollar	62,910	4,601	68,457	4,331
Nippon Food Supplies Company Pty Ltd (Austraria)	百 万 円 :Millions of Yen	5,733	419	6,332	400
東京共同貿易 Tokyo Mutual Trading Co., Ltd	百 万 円 :Millions of Yen	13,634	791	13,637	672
タカラバイオヨーロッパS.A.S. 連結	千 ユーロ :Thousands of Euro	35,142	1,329	32,066	Δ 1,353
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	4,854	183	4,841	Δ 204
宝生物工程(大連)	千 元 :Thousands of Yuan	277,254	72,579	201,259	15,289
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	5,406	1,415	3,964	301
宝日医生物技術(北京)	千 元 :Thousands of Yuan	553,735	84,306	353,023	30,647
Takara Biomedical Technology (Beijing) Co., Ltd.	百 万 円 :Millions of Yen	10,797	1,643	6,954	603
タカラコアバイオメディカル	百 万 ウォン :Millions of Won	14,260	2,307	14,200	2,441
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	1,451	234	1,519	261
タカラバイオDSSインド	千 インドルピー :Thousands of Rupee	612,174	47,856	406,524	37,666
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	1,022	79	691	64
タカラバイオUSA	千 US ドル :Thousands of US dollar	132,657	22,571	120,599	9,400
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	17,462	2,971	16,835	1,312

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2023		
	増減計 Total Change	売上差 Change in quantities	構成差 Change in sales composition
売上総利益 計 Gross profit	+1,989	Δ 108	+2,098
(参考) 原価コストダウン Δ 2,375 ※上記構成差に含む Reference :Cost reduction *Included in change in sales composition			

※利益の増加要因を「+」、減少要因を「Δ」で表示
*An increasing factor and a decreasing factor on profit are shown 「+」 and 「Δ」, respectively

⑤ 宝ホールディングス(連結) 業績予想 (p.10) における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.10)

		2023年3月期通期 実績		2024年3月期通期 予想	
		FY2023 Actual		FY2024 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ/loss)	売上高 Net Sales	営業利益 Operating income(Δ/loss)
ワイン輸入販売事業 Import and sale of wine		5,299	1,015	5,232	1,096
物流事業 Transportation		13,548	579	13,279	582
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)		503	415	506	413
その他 Other		11,599	283	11,412	278
「その他」計 Total "Other"		30,950	2,293	30,430	2,371